SBRT Boost in Prostate Cancer: Progress Made, Questions Remain
- 26 May 2025
- journal article
- Published by Wiley in The Prostate
- Vol. 85 (12) , 1155-1156
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable‐Intermediate and High‐Risk Prostate CancerThe Prostate, 2025
- Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate CancerThe Prostate, 2025
- The effect of dose‐escalation radiotherapy with simultaneous‐integrated‐boost on the use of short‐term androgen deprivation therapy in patients with intermediate risk prostate cancerThe Prostate, 2024
- Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patientsThe Prostate, 2023
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trialThe Lancet Oncology, 2021
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2021
- Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate CancerJAMA Network Open, 2019
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialJournal of Clinical Oncology, 2016